Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine to prevent microvascular complications in type 1 diabetes
NL-OMON59953Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of colchicine in diabetes mellitus type 1 (T1D), sponsored by Radboud University Medical Center. Primary endpoint: Change in vessel density on OCTA. Started Dec 2025; status: recruiting.
02
Drugs
colchicine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON59953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59953.